Med. praxi. 2011;8(12):514-518

Secondary endocrine hypertension

MUDr.Karolína Drbalová
ÚVN Praha

Secondary endocrine hypertension is 1–5 % of all hypertension. Etiology among them one of the primary hyperaldosteronism and other

mineralocorticoid hypertension, Cushing syndrome, pheochromocytoma, hyperparathyroidism, acromegaly, hyperthyroidism, hypothyroidism

and some other less common endocrine disorders. The first three are often among the causes of resistant hypertension. The

detection and elimination of a secondary cause may even mean a complete cure for the patient.

cortisol, aldosterone, metanephrines, parathormone, growth hormone.

Keywords: secondary hypertension, hyperaldosteronism, Cushing’s syndrome, pheochromocytoma, hyperparathyroidism, acromegaly,

Published: December 15, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drbalová K. Secondary endocrine hypertension. Med. praxi. 2011;8(12):514-518.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kaplan NM. Clinical hypertension, Philadelphia: Lippincott Williams and Wilkins, 2002: 550.
    2. Stowasser M. Primary hyperaldosteronism, J Hypertens, 2001; 19: 363-366. Go to original source... Go to PubMed...
    3. Stewart PM. Mineralocorticoid hypertension, Lancet 1999; 353: 1341-1347. Go to original source... Go to PubMed...
    4. Zelinka T, Štrauch B, Pecen L. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing´s syndrom. J Hum Hypertension, 2003. Go to original source...
    5. Weber KT. Heart-hitting tales of salt and destruction, J Lab Clin Med, 2000; 136: 7-13. Go to original source... Go to PubMed...
    6. Ciraku I, Kailasam MT, O´Connor DT, et al. Renal aldosterone excretion predicts early renal injury in human essential hypertension, J Am Soc Nephrol, 2000; 11: 354A.
    7. Janota T, Widimský J, Zelinka T, et al. Postižení srdce při primárním hyperaldosteronismu a esenciální hypertenzi stejné závažnosti. Cor Vasa, 2002; 44(5): 234-242.
    8. Lebel M. Usefulness of the Aldosterone-to-Renin Ratio for Screening Primary Aldosteronism, Hypertension Canada, 2003; 76: 1-4.
    9. Šindelka G, Widimský J, Haas T, et al. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment, Exp Clin Endocrinol Diabetes, 2000; 108: 353-361.
    10. Lim PO, Young WF, Macdonald TM. A rewies of the medical treatment of primary aldosteronism, J Hypertens 2001; 19: 353-361. Go to original source... Go to PubMed...
    11. Suzuki H, Handa M, Kondo K, et al. Role of renin angiotensin systém in glucocorticoid hypertension in rats, Am J Physiol Endocrinol Metab 1982; 243: E48-E51. Go to original source... Go to PubMed...
    12. Ďurovcová V, Kršek M. Cushingův syndrom - charakteristika, diagnostika, léčba, Medicína pro praxi 2009; 6(6): 295-297.
    13. Nieman LK. Diagnostic tests for Cushing´s syndrome, Ann NY Acad Sci, 2002; 970: 143-150. Go to original source... Go to PubMed...
    14. Papanicolau DA, Yanovski JA, Cutler GB, et al. A single midnight cortisol measurement distinguishes Cushing´s syndrome from pseudo-Cushingś states. J Clin Endocrinol Metab, 1998; 83: 1163-1167. Go to original source...
    15. Kaye TB, Crapo L. The Cushing´s syndrome: an update on diagnostic test. Ann intern Med, 1990; 112: 434-444. Go to original source... Go to PubMed...
    16. Kršek M, Matějovská H. Diferenciální diagnóza incidentalomů nadledvin a úloha zobrazovacích metod, Vnitřní lékařství 2002; 48: 409-415. Go to PubMed...
    17. Kršek M, Weiss V. Náhodně zjištěné expanzivní procesy selární oblasti. Časopis lékařů českých 2003; 142: 14-18.
    18. Marek J, Ježková J, Hána V, et al. Gamma knife radiosurgery for pituitary adenoma - 8 year experience. ENEA 2002, Abstract PA - 126, p. 90.
    19. Einsehofer G, Walrher MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinc biochemical and clinical phenotypes, J Clin Endocrinol Metab 2001; 86: 1999-2008. Go to original source... Go to PubMed...
    20. Manger WM, Gifford RW. Pheochromocytoma, J Clin Hypertens, 2002; 4: 62-72. Go to original source... Go to PubMed...
    21. Manger WM, Gifford R. Clinical and Experimental Pheochromocytoma, Oxford: Blackwell Science, 1996.
    22. Bravo EL, Tagle R. Pheochromocytoma: tate-of-the-art and future prospects. Endocr. Rev 2003; 24: 539-553. Go to original source... Go to PubMed...
    23. Raber W, Raffesberg W, Bischof, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma, Arch Intern Med 2000; 160: 2957-2963. Go to original source... Go to PubMed...
    24. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines, Clin Endocrinol Metab 2003; 88: 553-558. Go to original source... Go to PubMed...
    25. Walther M, Herring J, Choyke P, et al. Laparoscopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. J Urol, 1999; 164: 14-17. Go to original source...
    26. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome, Cancer Principles and Practice of Oncology 2001: 1813-1833.
    27. Mc Cormick D. Carcinoid tumors and syndrom, Gastroenterol. Nurs 2002; 25: 105-111. Go to original source... Go to PubMed...
    28. Plockinger U, Rindi G, et al. Guidelines fot the diagnosis and treatment of Neuroendocrine Tumors, Neuroendocrinology 2004; 80: 394-424. Go to original source... Go to PubMed...
    29. Boushey RP, Dackiw APB. Carcinoid tumors, Curr Treat Options Oncol. 2002; 3: 319-326. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.